8-K current report · filed Nov 4, 2026

Septerna, Inc. (SEPN) 8-K Current Report: November 4, 2026

Item 7.01Item EX-99.1Item EX-99.2SEPN overview

Short answer

Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). SEP-204 selected as development candidate for Graves’ disease and thyroid eye disease.

Septerna, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • SEP-204 selected as development candidate for Graves’ disease and thyroid eye disease
  • Preclinical SEP-204 data reported at the 2026 American Thyroid Association Annual Meeting
  • Updated corporate presentation signals additional investor-facing program information
  • Investors should review Exhibits 99.1 and 99.2 for supporting data and development details

Item EX-99.1 · Exhibit EX-99.1

  • SEP-204 selected as potential first-in-class oral TSHR NAM for Graves’ disease and thyroid eye disease
  • Preclinical models showed normalized T4, reduced thyroid enlargement and reduced orbital proptosis
  • Projected human half-life of 20-40 hours supports anticipated once-daily dosing
  • Generally well tolerated in 28-day GLP toxicology studies in rats and dogs
  • Phase 1 healthy-volunteer trial planned for Q1 2027, creating a key clinical execution milestone

Item EX-99.2 · Exhibit EX-99.2

  • SEP-479 Phase 1 SAD/MAD data anticipated Q1 2027, with observed 3-4 day half-life supporting once-daily dosing
  • SEP-204 Phase 1 initiation anticipated Q1 2027 for Graves’ disease and thyroid eye disease
  • SEP-631 Phase 1 showed robust pharmacodynamics, >99% receptor occupancy, and approximately 24-hour half-life supporting once-daily dosing
  • SEP-631 produced no severe or serious adverse events, with adverse-event rates comparable to placebo
  • Novo collaboration includes $195M upfront, approximately $500M milestones per program, and mid-to-high single-digit tiered royalties

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Septerna, Inc. 8-K filings

Get the next SEPN 8-K as it lands

Follow SEPN for push alerts, or ask the research agent what this filing means.